Toll-like receptor 9 agonists as cancer therapeutics

被引：53
作者：
Holtick, Udo [1 ,2 ]
Scheulen, Max E. [3 ]
von Bergwelt-Baildon, Michael S. [1 ,2 ]
Weihrauch, Martin R. [1 ,2 ]
机构：
[1] Univ Cologne, Dept Internal Med 1, D-50924 Cologne, Germany
[2] Univ Cologne, Lab Transplantat & Tumor Immunol, Max Eder Grp, D-50924 Cologne, Germany
[3] Univ Essen Gesamthsch, W German Canc Ctr, Dept Med Canc Res, Essen, Germany
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 03期
关键词：
cancer; immunotherapy; TLR9; agonists; vaccine; BACTERIAL CPG-DNA; PHASE-II TRIAL; NF-KAPPA-B; T-CELLS; IMMUNOSTIMULATORY ACTIVITY; DENDRITIC CELLS; MOLECULAR-PATTERNS; ANTITUMOR-ACTIVITY; INNATE IMMUNITY; GROWTH-FACTOR;
D O I：
10.1517/13543784.2011.553187
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Areas covered: This review summarizes TLR9 signaling and the impact of TLR9 agonists on the immune response. The most recent experimental and clinical data are analyzed as well as the development of new TLR9 agonists in current clinical trials. Expert opinion: Application of TLR9 agonists, in particular, combination strategies with chemo- or radiotherapy seem a promising and efficient immunotherapeutic approach in cancer patients even with refractory disease. Simultaneous application of TLR9 agonists aims at supporting the patient's immune response and overcoming specific immunosuppressant strategies developed by tumors. Combinatory approaches of the future might also seek for synergism of TLR9 agonists with other immunomodulatory strategies such as B-cell activation using the CD40--CD40L system.
引用
收藏
页码：361 / 372
页数：12
相关论文
共 50 条
  • [21] Trial Watch Toll-like receptor agonists for cancer therapy
    Vacchelli, Erika
    Eggermont, Alexander
    Sautes-Fridman, Catherine
    Galon, Jerome
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2013, 2 (08):
  • [22] Toll-like receptor agonists in oncological indications
    Aranda, Fernando
    Vacchelli, Erika
    Obrist, Florine
    Eggermont, Alexander
    Galon, Jerome
    Sautes-Fridman, Catherine
    Cremer, Isabelle
    ter Meulen, Jan Henrik
    Zitvogel, Laurence
    Kroemer, Guido
    Galluzzi, Lorenzo
    ONCOIMMUNOLOGY, 2014, 3 (06):
  • [23] Clinical investigations of Toll-like receptor agonists
    Meyer, Thomas
    Stockfleth, Eggert
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (07) : 1051 - 1065
  • [24] Antiviral applications of Toll-like receptor agonists
    Horscroft, Nigel J.
    Pryde, David C.
    Bright, Helen
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (04) : 789 - 801
  • [25] Recent clinical trends in Toll-like receptor targeting therapeutics
    Anwar, Muhammad Ayaz
    Shah, Masaud
    Kim, Jason
    Choi, Sangdun
    MEDICINAL RESEARCH REVIEWS, 2019, 39 (03) : 1053 - 1090
  • [26] Application of toll-like receptors (TLRs) and their agonists in cancer vaccines and immunotherapy
    Chakraborty, Samik
    Ye, Juan
    Wang, Herui
    Sun, Mitchell
    Zhang, Yaping
    Sang, Xueyu
    Zhuang, Zhengping
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [27] The Role of Toll-like Receptor Agonists and Their Nanomedicines for Tumor Immunotherapy
    Huang, Lingling
    Ge, Xiaoyan
    Liu, Yang
    Li, Hui
    Zhang, Zhiyue
    PHARMACEUTICS, 2022, 14 (06)
  • [28] Bibliometric analysis of toll-like receptor agonists associated with cancer therapy
    Li, Wei
    Wan, Li
    Duan, Shaojun
    Xu, Jingjing
    MEDICINE, 2022, 101 (01) : E28520
  • [29] New developments in Toll-like receptor targeted therapeutics
    Connolly, Dympna J.
    O'Neill, Luke A. J.
    CURRENT OPINION IN PHARMACOLOGY, 2012, 12 (04) : 510 - 518
  • [30] Toll-like receptor 2 suppresses Toll-like receptor 9 responses in Peyer's patch dendritic cells
    Kotaki, Ryutaro
    Wajima, Shun-ichi
    Shiokawa, Aya
    Hachimura, Satoshi
    IMMUNOBIOLOGY, 2015, 220 (06) : 734 - 743
12345